Header Logo

Connection

Laurel Habel to Follow-Up Studies

Back to Details
This is a "connection" page, showing publications Laurel Habel has written about Follow-Up Studies.
Laurel Habel
Connection Strength
0.976
Follow-Up Studies
  1. Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes. Diabetes Care. 2013 Dec; 36(12):3953-60.
    View in: PubMed
    Score: 0.091
  2. HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease. Breast Cancer Res. 2013 Mar 14; 15(2):R24.
    View in: PubMed
    Score: 0.087
  3. Screening pharmaceuticals for possible carcinogenic effects: initial positive results for drugs not previously screened. Cancer Causes Control. 2009 Dec; 20(10):1821-35.
    View in: PubMed
    Score: 0.069
  4. Thiazolidinedione therapy is not associated with increased colonic neoplasia risk in patients with diabetes mellitus. Gastroenterology. 2008 Dec; 135(6):1914-23, 1923.e1.
    View in: PubMed
    Score: 0.064
  5. Erratum: Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361 859 recipients. Pharmacoepidemiol Drug Saf. 2008 Jul; 17(7):751.
    View in: PubMed
    Score: 0.063
  6. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf. 2008 Jan; 17(1):27-36.
    View in: PubMed
    Score: 0.061
  7. Methylphenidate use in children and risk of cancer at 18 sites: results of surveillance analyses. Pharmacoepidemiol Drug Saf. 2007 Dec; 16(12):1268-72.
    View in: PubMed
    Score: 0.060
  8. Antibiotics and risk of breast cancer: up to 9 years of follow-up of 2.1 million women. Cancer Epidemiol Biomarkers Prev. 2006 Nov; 15(11):2102-6.
    View in: PubMed
    Score: 0.056
  9. Barbiturates and lung cancer: a re-evaluation. Int J Epidemiol. 1999 Jun; 28(3):375-9.
    View in: PubMed
    Score: 0.033
  10. Statin use and risk of multiple myeloma: An analysis from the cancer research network. Int J Cancer. 2017 08 01; 141(3):480-487.
    View in: PubMed
    Score: 0.029
  11. Feasibility of collecting tumor samples of breast cancer patients diagnosed up to 50 years ago in the Child Health and Development Studies. J Dev Orig Health Dis. 2017 Jun; 8(3):331-336.
    View in: PubMed
    Score: 0.029
  12. Effect of Race and Ethnicity on Antihypertensive Medication Utilization Among Women in the United States: Study of Women's Health Across the Nation (SWAN). J Am Heart Assoc. 2017 Feb 23; 6(3).
    View in: PubMed
    Score: 0.029
  13. Exercise and Risk of Cardiovascular Events in Women With Nonmetastatic Breast Cancer. J Clin Oncol. 2016 08 10; 34(23):2743-9.
    View in: PubMed
    Score: 0.027
  14. Risk Prediction for Local Breast Cancer Recurrence Among Women with DCIS Treated in a Community Practice: A Nested, Case-Control Study. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S502-8.
    View in: PubMed
    Score: 0.025
  15. Breastfeeding, PAM50 tumor subtype, and breast cancer prognosis and survival. J Natl Cancer Inst. 2015 Jul; 107(7).
    View in: PubMed
    Score: 0.025
  16. Characterization and treatment of local recurrence following breast conservation for ductal carcinoma in situ. Ann Surg Oncol. 2014 Nov; 21(12):3766-73.
    View in: PubMed
    Score: 0.024
  17. Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer. Pharmacoepidemiol Drug Saf. 2014 Jun; 23(6):636-45.
    View in: PubMed
    Score: 0.023
  18. Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics. Cancer Epidemiol Biomarkers Prev. 2014 May; 23(5):714-24.
    View in: PubMed
    Score: 0.023
  19. Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomes. Cancer Epidemiol Biomarkers Prev. 2014 May; 23(5):725-34.
    View in: PubMed
    Score: 0.023
  20. Racial/ethnic differences in use and duration of adjuvant hormonal therapy for breast cancer in the women's health initiative. Cancer Epidemiol Biomarkers Prev. 2013 Mar; 22(3):365-73.
    View in: PubMed
    Score: 0.021
  21. Ten-year risk of diagnostic mammograms and invasive breast procedures after breast-conserving surgery for DCIS. J Natl Cancer Inst. 2012 Apr 18; 104(8):614-21.
    View in: PubMed
    Score: 0.020
  22. Risk of cancer in patients exposed to gabapentin in two electronic medical record systems. Pharmacoepidemiol Drug Saf. 2012 Feb; 21(2):214-25.
    View in: PubMed
    Score: 0.020
  23. Reproductive and menstrual factors and risk of ductal carcinoma in situ of the breast in a cohort of postmenopausal women. Cancer Causes Control. 2011 Oct; 22(10):1415-24.
    View in: PubMed
    Score: 0.019
  24. Statin use and risk of colorectal cancer in a cohort of middle-aged men in the US: a prospective cohort study. Drugs. 2009 Jul 30; 69(11):1445-57.
    View in: PubMed
    Score: 0.017
  25. Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial. J Natl Cancer Inst. 2008 Apr 16; 100(8):563-71.
    View in: PubMed
    Score: 0.015
  26. The risk for malignant primary adult-onset glioma in a large, multiethnic, managed-care cohort: cigarette smoking and other lifestyle behaviors. J Neurooncol. 2004 May; 68(1):57-69.
    View in: PubMed
    Score: 0.012
  27. Risk of subsequent cancer following invasive or in situ squamous cell skin cancer. Ann Epidemiol. 2002 Oct; 12(7):469-75.
    View in: PubMed
    Score: 0.011

© 2024 Kaiser Permanente